Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors:: a study of 182 cases from the Spanish Neuroblastoma Registry

被引:25
作者
Burgues, Octavio
Navarro, Samuel
Noguera, Rosa
Pellin, Antonio
Ruiz, Amparo
Castel, Victoria
Llombart-Bosch, Antonio
机构
[1] Fac Med Valencia, Dept Patol, E-46010 Valencia, Spain
[2] Univ Valencia, Hosp La Fe, Valencia, Spain
关键词
neuroblastoma; neuroblastic tumors; pediatric tumors;
D O I
10.1007/s00428-006-0253-y
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
In addition to clinical and biological factors, further valuable prognostic information in neuroblastoma (Schwannian stroma-poor) (NB) patients is provided by the histopathologic analysis and the application of the International Neuroblastoma Pathology Classification (INPC) system. The objective of this study was to assess the prognostic impact of the INPC classification in a series of NB (Schwannian stroma-poor) and its relation with other prognostic factors. One hundred eighty-two cases of NB were collected from the files of the Spanish Neuroblastoma Registry. Slides were reviewed, and NB cases were grouped into favorable and unfavorable categories according to INPC criteria, taking into account morphological features (mitosis-karyorrhexis index, histological subtype) and patient's age at diagnosis. Other pathological [presence of calcifications, tissular components, and number of mitotic cells per 10 high-power field (HPF)], immunohistochemical (P-glycoprotein and Ki-67 protein expression) and genetic (MYCN amplification and chromosome 1p deletion) features were also studied. Statistical analyses of overall survival with Kaplan-Meier curves and a multivariate study using Cox regression were performed (40.3% of NBs were considered favorable and 59.7% unfavorable). Unfavorable NB showed a mean survival time of 57 months compared with 89 months in favorable cases. Advanced stage, more than ten mitoses per 10 HPF, Ki-67 expression in more than 30% of tumor cells, MYCN oncogene amplification and chromosome 1p deletion were observed more frequently in unfavorable NB. The Cox regression analysis demonstrated that clinical stage (International Neuroblastoma Staging System stage 4) and histological subtype (undifferentiated NB) were the most important factors that influence the overall survival (p < 0.001). INPC classification results are major prognostic indicators in NB and should be considered in the therapeutic stratification of NB patients.
引用
收藏
页码:410 / 420
页数:11
相关论文
共 67 条
[1]   Morphologic features of neuroblastoma (Schwannian stroma-poor tumors) in clinically favorable and unfavorable groups [J].
Ambros, IM ;
Hata, J ;
Joshi, VV ;
Roald, B ;
Dehner, LP ;
Tüchler, H ;
Pötschger, U ;
Shimada, H .
CANCER, 2002, 94 (05) :1574-1583
[2]   Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines [J].
Ambros, PF ;
Ambros, IM .
MEDICAL AND PEDIATRIC ONCOLOGY, 2001, 37 (06) :492-504
[3]  
Beckwith J B, 1968, J Pediatr Surg, V3, P106
[4]   Comparative genomic hybridization and telomerase activity analysis identify two biologically different groups of 4s neuroblastomas [J].
Brinkschmidt, C ;
Poremba, C ;
Christiansen, H ;
Simon, R ;
Schäfer, KL ;
Terpe, HJ ;
Lampert, F ;
Boecker, W ;
Dockhorn-Dworniczak, B .
BRITISH JOURNAL OF CANCER, 1998, 77 (12) :2223-2229
[5]   AMPLIFICATION OF N-MYC IN UNTREATED HUMAN NEUROBLASTOMAS CORRELATES WITH ADVANCED DISEASE STAGE [J].
BRODEUR, GM ;
SEEGER, RC ;
SCHWAB, M ;
VARMUS, HE ;
BISHOP, JM .
SCIENCE, 1984, 224 (4653) :1121-1124
[6]   REVISIONS OF THE INTERNATIONAL CRITERIA FOR NEUROBLASTOMA DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT [J].
BRODEUR, GM ;
PRITCHARD, J ;
BERTHOLD, F ;
CARLSEN, NLT ;
CASTEL, V ;
CASTLEBERRY, RP ;
DEBERNARDI, B ;
EVANS, AE ;
FAVROT, M ;
HEDBORG, F ;
KANEKO, M ;
KEMSHEAD, J ;
LAMPERT, F ;
LEE, REJ ;
LOOK, AT ;
PEARSON, ADJ ;
PHILIP, T ;
ROALD, B ;
SAWADA, T ;
SEEGER, RC ;
TSUCHIDA, Y ;
VOUTE, PA .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) :1466-1477
[7]   INTERNATIONAL CRITERIA FOR DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT IN PATIENTS WITH NEURO-BLASTOMA [J].
BRODEUR, GM ;
SEEGER, RC ;
BARRETT, A ;
BERTHOLD, F ;
CASTLEBERRY, RP ;
DANGIO, G ;
DEBERNARDI, B ;
EVANS, AE ;
FAVROT, M ;
FREEMAN, AI ;
HAASE, G ;
HARTMANN, O ;
HAYES, FA ;
HELSON, L ;
KEMSHEAD, J ;
LAMPERT, F ;
NINANE, J ;
OHKAWA, H ;
PHILIP, T ;
PINKERTON, CR ;
PRITCHARD, J ;
SAWADA, T ;
SIEGEL, S ;
SMITH, EI ;
TSUCHIDA, Y ;
VOUTE, PA .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (12) :1874-1881
[9]   MONOCLONAL-ANTIBODY KI-67 - ITS USE IN HISTOPATHOLOGY [J].
BROWN, DC ;
GATTER, KC .
HISTOPATHOLOGY, 1990, 17 (06) :489-503
[10]   Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma [J].
Caron, H ;
vanSluis, P ;
deKraker, J ;
Bokkerink, J ;
Egeler, M ;
Laureys, G ;
Slater, R ;
Westerveld, A ;
Voute, PA ;
Versteeg, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (04) :225-230